Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia

Neurology

Volumn 65, Issue 9, 2005, Pages 1423-1429

  Comella, Cynthia L ^a   Jankovic, J ^b   Shannon, K M ^a   Tsui, J ^c   Swenson, M ^d   Leurgans, S ^a   Fan, W ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B;

ADULT; AGED; ARTICLE; CERVICAL DYSTONIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DYSPHAGIA; DYSTONIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE WEAKNESS; NECK PAIN; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; XEROSTOMIA;

EID: 27644442316     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000183055.81056.5c     Document Type: Article

References (38)

1. Jankovic J, Leder S, Warner D, Schwartz K. Cervical dystonia: clinical findings and associated movement disorders. Neurology 1991;41:1088-1091.
2. Jankovic J. Treatment of cervical dyatonia with botulinum toxin. Mov Disord 2004;19 (suppl 8):S109-S115.
3. Comella CL, Jankovic J, Brin MF. Use of botulinum toxin type A in the treatment of cervical dystonia. Neurology 2000;55:S15-S21.
4. Greene P, Kang U, Fahrt S, et al. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 1990;40:1213-1218.
5. Jankovic J, Schwartz K. Botulinum toxin injections for cervical dystonia. Neurology 1990;40:277-280.
6. Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999;53:1439-1446.
7. Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999;53:1431-1438.
8. Hamjian JA, Walker FO. Serial neurophysiological studies of intramuscular botulinum-A toxin in humans. Muscle Nerve 1994;17:1385-1392.
9. Setler P. The biochemistry of botulinum toxin type B. Neurology 2000;55:322-28.
10. Schiavo G, Rossetto O, Tonello F, Montecucco C. Intracellular targets and metalloprotease activity of tetanus and botulism neurotoxins. Curr Top Microbiol Immunol 1995;195:257-274.
11. Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache 2003;43 (suppl 1):S16-S24.
12. de Paiva A, Ashton AC, Foran P, et al. Botulinum A like type B and tetanus toxins fulfils criteria for being a zinc-dependent protease. J Neurochem 1993;61:2338-2341.
13. Consky ELA. Clinical assessments of patients with cervical dystonia. In: Jankovic J, Hallett M, eds. Therapy with botulinum toxin. New York: Marcel Dekker, 1994:211-237.
14. Comella CL, Stebbins GT, Goetz CG, et al. Teaching tape for the motor section of the Toronto Western Spasmodic Torticollis Scale. Mov Disord 1997;12:570-575.
15. Hanna PA, Jankovic J. Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology 1998;50:1624-1629.
16. Comella CL, Buchman AS, Tanner CM, et al. Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance. Neurology 1992;42:878-882.
17. Lew MF, Adornato BT, Duane DD, et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 1997;49:701-707.
18. Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 1987;37:616-623.
19. Tsui JK, Eisen A, Stoessl AJ, et al. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 1986;2:245-247.
20. Ceballos-Baumann AO. Evidence-based medicine in botulinum oxin therapy for cervical dystonia. J Neurol 2001;248 (suppl 1):14-20.
21. Sloop RR, Cole BA, Escutin RO. Human response to botulinum toxin injection: type B compared with type A. Neurology 1997;49:189-194.
22. Eleopra R, Tugnoli V, Quatrale R, et al. Different types of botulinum toxin in humans. Mov Disord 2004;19 (suppl 8):S53-S59.
23. Braahear A, Watts MW, Marchetti A, et al. Duration of effect of botulinum toxin type A in adult patients with cervical dystonia: a retrospective chart review. Clin Ther 2000;22:1516-1524.
24. Kessler KR, Skutta M, Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol 1999;246:265-274.
25. Racette BA, McGee-Minnich L, Perlmutter JS. Efficacy and safety of a new bulk toxin of botulinum toxin in cervical dystonia: a blinded evaluation. Clin Neuropharmacol 1999;22:337-339.
26. Lew MF. Duration of effectiveness of botulinum toxin type B in the treatment of cervical dystonia. Adv Neurol 2004;94:211-215.
27. Aoki KR. Pharmacology and immunology of botulinum toxin serotypes. J Neurol 2001;248 (suppl 1):3-10.
28. de Paiva A, Meunier FA, Molgo J, et al. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 1999;96:3200-3205.
29. Fernandez-Salas E, Ho H, Garay P, et al. Is the light chain subcellular localization an important factor in botulinum toxin duration of action? Mov Disord 2004;19 (suppl 8):S23-S34.
30. Whelchel DD, Brehmer TM, Brooks PM, et al. Molecular targets of botulinum toxin at the mammalian neuromuscular junction. Mov Disord 2004;19 (suppl 8):S7-S16.
31. Borodic GE, Joseph M, Fay L, et al. Botulinum A toxin for the treatment of spasmodic torticollis: dysphagia and regional toxin spread. Head Neck 1990;12:392-399.
32. Borodic GE, Ferrante R, Pearce LB, Smith K. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections. Mov Disord 1994;9:31-39.
33. Borodic GE, Pearce LB, Smith KL, et al. Botulinum B toxin as an alternative to botulinum A toxin: a histologic study. Ophthal Plast Reconstr Surg 1993;9:182-190.
34. Shaari CM, Sanders I. Quantifying how location and dose of botulinum toxin injections affect muscle paralysis. Muscle Nerve 1993;16:964-969.
35. Flynn TC, Clark RE II. Botulinum toxin type B (MYOBLOC) versus botulinum toxin type A (BOTOX) frontalis study: rate of onset and radius of diffusion. Dermatol Surg 2003;29:519-522.
36. Arezzo JC, Litwak MS, Caputo FA, et al. Paralytic effects of BoNT-A VS BoNT-B in injected and non-injected muscles: implications to toxin therapy. Pain Med 2001;2:239.
37. Dressier D, Benecke R. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 2003;49:34-38.
38. Racette BA, Lopate G, Good L, et al. Ptosis as a remote effect of therapeutic botulinum toxin B injection. Neurology 2002;59:1445-1447.